Huey-ming Lo1, Tsung-hsuan Lai2, Chih-hung Li3, Wen-bin Wu3. 1. 1] School of Medicine, Fu-Jen Catholic University, New Taipei City, Taiwan, China [2] Section of Cardiology, Department of Internal Medicine, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan, China. 2. 1] School of Medicine, Fu-Jen Catholic University, New Taipei City, Taiwan, China [2] Department of Obstetrics and Gynecology, Cathay General Hospital, Taipei, Taiwan, China [3] Institute of Systems Biology and Bioinformatics, National Central University, Jhongli City, Taoyuan, Taiwan, China. 3. School of Medicine, Fu-Jen Catholic University, New Taipei City, Taiwan, China.
Abstract
AIM: Chemokines usually direct the movement of circulating leukocytes to sites of inflammation or injury. CXCL1/GRO-α has been shown to be upregulated in atherosclerotic lesions and various cancers. The aim of this study was to investigate the mechanisms underlying the TNF-α-induced release of CXCL1 from human vascular endothelial cells in vitro. METHODS: Human umbilical vein endothelial cells (HUVECs) were treated with different proinflam-matory mediators and growth factors. CXCL1 expression and secretion were determined using RT-PCR and ELISA, respectively. TNF-α-induced cell signaling was assayed with Western blotting. Cell viability/growth was determined using MTT assay. Monocyte migration was measured with transwell migration assay. RESULTS: Among the 17 mediators and growth factors tested, TNF-α, LPS and thrombin induced marked increase in CXCL1 release from HUVEC cells. TNF-α (2, 5 ng/mL) induced CXCL1 release and mRNA expression in the cells in concentration- and time-dependent manners. TNF-α (5 ng/mL) caused activation of JNK, p38 MAPK, PI3K and Akt, whereas pretreatment with JNK inhibitor (SP600125), p38 MAPK inhibitor (SB202190) or PI-3K inhibitor (LY294002) significantly suppressed TNF-α-induced CXCL1 release from the cells. But only SP600125 significantly reduced TNF-α-induced CXCL1 mRNA expression in the cells. Moreover, dexamethasone (up to 500 nmol/L) failed to affect TNF-α-induced CXCL1 release from the cells. In functional studies, recombinant CXCL1 enhanced HUVEC proliferation, and both recombinant CXCL1 and TNF-α-induced CXCL1 from HUVECs attracted human monocyte migration. CONCLUSION: TNF-α stimulates CXCL1 release from human ECs through JNK-mediated CXCL1 mRNA expression and p38 MAPK- and PI-3K-mediated CXCL1 secretory processes.
AIM: Chemokines usually direct the movement of circulating leukocytes to sites of inflammation or injury. CXCL1/GRO-α has been shown to be upregulated in atherosclerotic lesions and various cancers. The aim of this study was to investigate the mechanisms underlying the TNF-α-induced release of CXCL1 from human vascular endothelial cells in vitro. METHODS:Human umbilical vein endothelial cells (HUVECs) were treated with different proinflam-matory mediators and growth factors. CXCL1 expression and secretion were determined using RT-PCR and ELISA, respectively. TNF-α-induced cell signaling was assayed with Western blotting. Cell viability/growth was determined using MTT assay. Monocyte migration was measured with transwell migration assay. RESULTS: Among the 17 mediators and growth factors tested, TNF-α, LPS and thrombin induced marked increase in CXCL1 release from HUVEC cells. TNF-α (2, 5 ng/mL) induced CXCL1 release and mRNA expression in the cells in concentration- and time-dependent manners. TNF-α (5 ng/mL) caused activation of JNK, p38 MAPK, PI3K and Akt, whereas pretreatment with JNK inhibitor (SP600125), p38 MAPK inhibitor (SB202190) or PI-3K inhibitor (LY294002) significantly suppressed TNF-α-induced CXCL1 release from the cells. But only SP600125 significantly reduced TNF-α-induced CXCL1 mRNA expression in the cells. Moreover, dexamethasone (up to 500 nmol/L) failed to affect TNF-α-induced CXCL1 release from the cells. In functional studies, recombinant CXCL1 enhanced HUVEC proliferation, and both recombinant CXCL1 and TNF-α-induced CXCL1 from HUVECs attracted human monocyte migration. CONCLUSION: TNF-α stimulates CXCL1 release from human ECs through JNK-mediated CXCL1 mRNA expression and p38 MAPK- and PI-3K-mediated CXCL1 secretory processes.
Authors: Ralph G DePalma; Virginia W Hayes; H Treat Cafferata; Hamid A Mohammadpour; Bruce K Chow; Leo R Zacharski; Mark R Hall Journal: J Surg Res Date: 2003-05-15 Impact factor: 2.192
Authors: Patrizia Scapini; Monica Morini; Cristina Tecchio; Simona Minghelli; Emma Di Carlo; Elena Tanghetti; Adriana Albini; Clifford Lowell; Giorgio Berton; Douglas M Noonan; Marco A Cassatella Journal: J Immunol Date: 2004-04-15 Impact factor: 5.422
Authors: A G Jarnicki; H Schilter; G Liu; K Wheeldon; A-T Essilfie; J S Foot; T T Yow; W Jarolimek; P M Hansbro Journal: Br J Pharmacol Date: 2016-10-12 Impact factor: 8.739
Authors: Salai Madhumathi Parkunan; C Blake Randall; Roger A Astley; Glaucia C Furtado; Sergio A Lira; Michelle C Callegan Journal: J Leukoc Biol Date: 2016-06-10 Impact factor: 4.962
Authors: Natasha Whibley; Jillian R Jaycox; Delyth Reid; Abhishek V Garg; Julie A Taylor; Cornelius J Clancy; M Hong Nguyen; Partha S Biswas; Mandy J McGeachy; Gordon D Brown; Sarah L Gaffen Journal: J Immunol Date: 2015-09-02 Impact factor: 5.422